Norihiro Matsuura

Osaka International Cancer Institute

Papers

3

Total Citations

25

H-Index

2

About

Norihiro Matsuura is a leading surgical oncologist whose work centers on advanced gastric and gastroesophageal junction cancers, with a particular focus on novel targeted therapies and minimally invasive surgical techniques. His major contributions include pioneering real-world evidence on the adverse effects of zolbetuximab—a CLDN18.2-targeting antibody—demonstrating its efficacy in HER2-negative patients while documenting rare complications like protein-losing enteropathy (13 citations). He has also advanced the field of conversion surgery, showing that zolbetuximab-based chemotherapy can enable successful resection in previously inoperable CLDN18.2-positive tumors. In comparative surgical outcomes, Matsuura’s research on robotic versus laparoscopic gastrectomy (10 citations) provides critical perioperative and three-year survival data, helping refine treatment algorithms. His work bridges the gap between clinical trials and real-world practice, offering actionable insights for managing complex gastric cancer cases. With a growing citation impact and a focus on translating molecular targets into surgical strategies, Matsuura is shaping the next generation of multimodal, precision-driven gastric cancer care.

Research Focus

Key Achievements

2
H-Index
3
Papers
25
Total Citations
8
Avg Citations/Paper
🏆 Most Cited Paper
Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer
13 citations · 2025
📈 Most Prolific Year: 2025 (3 Papers)
🤝 Key Collaborators: 31
🏛 Institutions: Osaka International Cancer Institute

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago